Christopher Brittain

2.1k total citations · 2 hit papers
21 papers, 1.5k citations indexed

About

Christopher Brittain is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Christopher Brittain has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Ophthalmology, 13 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Christopher Brittain's work include Retinal Diseases and Treatments (15 papers), Retinal Imaging and Analysis (12 papers) and Glaucoma and retinal disorders (10 papers). Christopher Brittain is often cited by papers focused on Retinal Diseases and Treatments (15 papers), Retinal Imaging and Analysis (12 papers) and Glaucoma and retinal disorders (10 papers). Christopher Brittain collaborates with scholars based in United Kingdom, United States and Switzerland. Christopher Brittain's co-authors include Erin C. Henry, Srinivas R. Sadda, Daniela Ferrara, Frank G. Holz, Paul Mitchell, Monika Fleckenstein, K. Bailey Freund, Menno van Lookeren Campagne, David S. Boyer and Ursula Schmidt‐Erfurth and has published in prestigious journals such as Ophthalmology, Investigative Ophthalmology & Visual Science and European Journal of Applied Physiology.

In The Last Decade

Christopher Brittain

21 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

2017 377 citations Monika Fleckenstein, Paul Mitchell et al. Ophthalmology profile →
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration

2018 264 citations Frank G. Holz, Srinivas R. Sadda et al. JAMA Ophthalmology profile →

Peers

Countries citing papers authored by Christopher Brittain

Since Specialization

Citations

This map shows the geographic impact of Christopher Brittain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Brittain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Brittain more than expected).

Fields of papers citing papers by Christopher Brittain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Brittain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Brittain. The network helps show where Christopher Brittain may publish in the future.

Co-authorship network of co-authors of Christopher Brittain

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Brittain. A scholar is included among the top collaborators of Christopher Brittain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Brittain. Christopher Brittain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion 2024 ·Ophthalmology ·Ramin Tadayoni, Liliana P Paris, Carl J. Danzig, Francis Abreu, Arshad M. Khanani, Christopher Brittain, Timothy Y. Y. Lai, Zdenka Hašková, Taiji Sakamoto, Aachal Kotecha, Patricio G. Schlottmann, Ying Liu, András Seres, (unknown), Jeffrey R. Willis, Young Hee Yoon	29
2	Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials 2021 ·Investigative Ophthalmology & Visual Science ·Arshad M. Khanani, Jeffrey S. Heier, Carlos Quezada-Ruiz, Hugh Lin, David G. Silverman, Christopher Brittain, (unknown), Balakumar Swaminathan, Karen Basu, Tien Yin Wong	5
3	Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2021 ·Ophthalmology ·Nancy M. Holekamp, Peter A. Campochiaro, Margaret Chang, Daniel M. Miller, Dante J. Pieramici, Anthony P. Adamis, Christopher Brittain, (unknown), Derrick Kaufman, Katie F. Maass, (unknown), Shrirang V. Ranade, Natasha Singh, Giulio Barteselli, Carl D. Regillo	121
4	Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk Factors 2020 ·Ophthalmology Retina ·Usha Chakravarthy, Clare Bailey, Peter H. Scanlon, Martin McKibbin, Rehna Khan, Sajjad Mahmood, Louise Downey, Narendra Dhingra, Christopher Brand, Christopher Brittain, Jeffrey R. Willis, (unknown), (unknown), Ronald A. Cantrell	43
5	Initial lesion growth rates and other baseline prognostic factors can improve the design of clinical trials in Geographic Atrophy (GA) 2020 ·Investigative Ophthalmology & Visual Science ·Michel Friesenhahn, Christina Rabe, Simon S. Gao, (unknown), Phillip Lai, Daniela Ferrara, Christopher Brittain, Lee Honigberg	2
6	Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade 2020 ·Eye ·Anthony P. Adamis, Christopher Brittain, (unknown), J. Jill Hopkins	45
7	Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United Kingdom 2019 ·Ophthalmology Retina ·Usha Chakravarthy, Clare Bailey, Peter H. Scanlon, Martin McKibbin, Rehna Khan, Sajjad Mahmood, Louise Downey, Narendra Dhingra, Christopher Brand, Christopher Brittain, Jeffrey R. Willis, (unknown), (unknown), Ronald A. Cantrell	6
8	Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs) 2018 ·Investigative Ophthalmology & Visual Science ·Dante J. Pieramici, Frank G. Holz, Jeffrey S. Heier, Srinivas R. Sadda, Brandon Busbee, Emily Y. Chew, Paul Mitchell, Adnan Tufail, Christopher Brittain, Daniela Ferrara, Sarah Gray, Lee Honigberg, (unknown), Barbara Tong, Jason S. Ehrlich, Neil M. Bressler	2
9	Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration 2018 ·Ophthalmology ·Usha Chakravarthy, Clare Bailey, Robert L. Johnston, Martin McKibbin, Rehna Khan, Sajjad Mahmood, Louise Downey, Narendra Dhingra, Christopher Brand, Christopher Brittain, Jeffrey R. Willis, (unknown), (unknown), Ronald A. Cantrell	84
10	Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration breakdown → 2018 ·JAMA Ophthalmology ·Frank G. Holz, Srinivas R. Sadda, Brandon Busbee, Emily Y. Chew, Paul Mitchell, Adnan Tufail, Christopher Brittain, Daniela Ferrara, Sarah Gray, Lee Honigberg, (unknown), Barbara Tong, Jason S. Ehrlich, Neil M. Bressler, (unknown)	264
11	The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration breakdown → 2017 ·Ophthalmology ·Monika Fleckenstein, Paul Mitchell, K. Bailey Freund, Srinivas R. Sadda, Frank G. Holz, Christopher Brittain, Erin C. Henry, Daniela Ferrara	377
12	THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET 2016 ·Retina ·David S. Boyer, Ursula Schmidt‐Erfurth, Menno van Lookeren Campagne, Erin C. Henry, Christopher Brittain	182
13	CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION 2016 ·Retina ·Srinivas R. Sadda, Usha Chakravarthy, David G. Birch, Giovanni Staurenghi, Erin C. Henry, Christopher Brittain	100
14	Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment 2015 ·Ophthalmology ·Ian Pearce, Sanjiv Banerjee, Ben Burton, Usha Chakravarthy, Louise Downey, Richard Gale, Jonathan Gibson, Sergio Pagliarini, Jignesh Patel, Sobha Sivaprasad, (unknown), Christopher Brittain, James Warburton	37
15	Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study 2013 ·Eye ·Adnan Tufail, Praveen J. Patel, Sobha Sivaprasad, Winfried M. K. Amoaku, Andrew C. Browning, Michael D. Cole, Richard Gale, Sheena George, Andrew Lotery, M. A. Majid, Martin McKibbin, Geeta Menon, Yit C. Yang, (unknown), Christopher Brittain, Aaron Osborne	38
16	Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR Study 2013 ·Ophthalmology ·Adnan Tufail, Nirodhini Narendran, Praveen J. Patel, Sobha Sivaprasad, Winfried M. K. Amoaku, Andrew C. Browning, (unknown), (unknown), Sheena George, Andrew Lotery, M. A. Majid, Martin McKibbin, Geeta Menon, C.D. Andrews, Christopher Brittain, Aaron Osborne, Yit C. Yang	76
17	Haemolytic uraemic syndrome preceding acute lymphoblastic leukaemia 2011 ·BMJ Case Reports ·Brandon Piel, Christopher Brittain, (unknown)	3
18	Changes in Scanning Laser Polarimetry Before and After Laser Capsulotomy for Posterior Capsular Opacification 2007 ·Journal of Glaucoma ·Christopher Brittain, Kenneth Choong Sian Fong, C.C. Hull, (unknown)	5
19	Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03% 2006 ·Advances in Therapy ·Christopher Brittain, Rohit Saxena, Andrew Waldock	9
20	Effect of prior metabolic rate on the kinetics of oxygen uptake during moderate-intensity exercise 2001 ·European Journal of Applied Physiology ·Christopher Brittain, Harry B. Rossiter, John M. Kowalchuk, Brian J. Whipp	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact